Chronic migraine headaches can interfere with work, family, and leisure.
Medications may not manage the pain, nausea, dizziness and other symptoms associated with migraines. This trial may help people suffering from chronic migraines maintain their lifestyle better – and it pays!
Cluster Headache is one of the most painful types of headaches. It’s frequently described as pain that occurs around, behind, or above the eye and along the temple in cyclic patterns or “clusters.” There are more than 200,000 cases of Cluster Headaches in the U.S. per year, and many patients describe it as a “drilling” type of sensation.
Right now, a local clinical research study is testing an investigational medication to see if it may help people who suffer from cluster headache (Investigational means the medication isn’t approved for routine clinical use).
If you qualify for this research study, you may have the opportunity to try this investigational medication. You may also receive study-related care at no cost, and compensation may be provided.
Learn more about this study here: http://curec.lk/1Uaj36v
Held every September, this Capitol Hill Day event continues the momentum established in 2013, and includes nearly 300 national organizations coming together in support of the Rally for Medical Research.
The purpose of the Rally is to call on our nation’s policymakers to make funding for National Institutes of Health (NIH) a national priority and raise awareness about the importance of continued investment in medical research that leads to MORE PROGRESS, MORE HOPE and MORE LIVES SAVED.
The next Rally for Medical Research Hill Day is Sept. 22, 2016.
Sign up to receive updates, including a link to register once it becomes available.
Exelixis, Inc. (EXEL – Analyst Report) announced positive top-line data from the phase II trial, CABOSUN, on Cabometyx in patients suffering from previously untreated advanced renal cell carcinoma (RCC).
Results showed that Cabometyx led to significant improvement in progression-free survival in patients with previously untreated advanced RCC, compared with sunitinib. Consequently, the trial met its primary endpoint.
Safety data from the Cabometyx arm of the study were consistent with those observed in previous studies in patients with advanced RCC.
Final results of the trial will be presented at a medical conference shortly.
We remind investors that Cabometyx (the tablet formulation of cabozantinib) was approved by the FDA in Apr 2016 for the treatment of patients with advanced RCC, who have received prior anti-angiogenic therapy.
Meanwhile, the European Medicines Agency (EMA) has accepted a Marketing Authorisation Application (MAA) for Cabometyx for review in the same indication. Upon a potential approval, the drug would be marketed in the EU by Exelixis’ partner, Ipsen. The MAA has been granted accelerated assessment by the EMA’s Committee for Medicinal Products for Human Use (CHMP), which translates a review period of 150 days instead of the standard 210 days.
Exelixis also plans to submit results of the CABOSUN trial to regulatory authorities in order to discuss further development of Cabometyx and submission strategy for the treatment of first-line advanced RCC.
As per the American Cancer Society, kidney cancer is one of the top 10 most commonly diagnosed forms of cancer in both men and women in the U.S. Hence, approval of Cabometyx in first-line advanced RCC will boost its growth prospects significantly.
Exelixis currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Abbott Laboratories (ABT – Analyst Report) , Johnson & Johnson (JNJ – Analyst Report) and Sanofi (SNY – Analyst Report) . All three stocks carry a Zacks Rank #2 (Buy).
From https://www.zacks.com/stock/news/218403/exelixis-kidney-cancer-drug-cabometyx-positive-in-phase-ii
Osteoarthritis Research Studies. Knee and hip arthritis studies enrolling now. No-cost medication. http://curec.lk/1VL5hu9
The purpose of this study is to investigate whether the study medication can help people with mild to moderate Alzheimer’s Disease improve their mental abilities such as understanding, reasoning, and judgment. The study medication will be given together with an FDA-approved Alzheimer’s medication: Aricept® (donepezil), Exelon® (rivastigmine) or Razadyne® (galantamine).
More about the study:
If you are interested, please find the full study details and eligibility criteria listed here.
Eligibility Criteria:
Participants must:
Participants must not:
Please complete the online questionnaire to check if you’re eligible for the trial.
If you’re not familiar with clinical trials, here are some FAQs:
Clinical trials are research studies to determine whether investigational drugs or treatments are safe and effective for humans. All new investigational medications and devices must undergo several clinical trials, often involving thousands of people.
You will have access to new investigational treatments that would be available to the general public only upon approval. You will also receive study-related medical care and attention from clinical trial staff at research facilities. Clinical trials offer hope for many people and an opportunity to help researchers find better treatments for others in the future.
Just another blog!
No hidden agendas, no politics, no absolutes – just seeking Christ together.
Upper Hands Piano: A Method for Adults 50+ to Spark the Mind, Heart and Soul
Separating Endocrinology from Quackery
Some things in mathematical logic that I find interesting
Little Free Library
O'Connor Music Studio Blog
Transition, excitement and probably a few tears
A Web Design Company
Support for Women
Official Fairfax County Government Emergency Preparedness, Response and Recovery Website
Economic and management consulting firm
STORIES WITH NO BOOKS
Be your best self through better health!
MaryO'Medical 